ARS Pharmaceuticals, Inc. splits its revenue into 3 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Product at $26.2 million, 78% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
117
|
34
|
23
|
28
|
33
|
16
|
8
|
87
|
2
|
| Product |
95
share 81.5%
|
26
+104.8%
share 77.9%
|
17
+124.8%
share 76.9%
|
20
+204.0%
share 72.4%
|
31
+5410.6%
share 96.3%
|
13
share 81.4%
|
8
share 97.4%
|
7
share 7.7%
|
1
share 27.5%
|
| Revenue Under Supply Agreements |
12
share 10.4%
|
7
+2188.2%
share 22.0%
|
3
share 12.1%
|
1
share 3.2%
|
1
share 3.5%
|
0
share 2.1%
|
—
|
—
|
—
|
| Revenue Under Collaboration Agreements |
9
-88.7%
share 8.1%
|
0
-97.8%
share 0.2%
|
2
+1085.2%
share 11.0%
|
7
-91.4%
share 24.4%
|
0
-96.3%
share 0.2%
|
3
share 16.5%
|
0
share 2.6%
|
80
share 91.9%
|
2
share 72.5%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SPRY (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1671858
- Former names
- Silverback Therapeutics, Inc. (until Nov 8, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.